Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Total Stock Market ETF (NY:VTI)

339.91 -2.38 (-0.70%)
Streaming Delayed Price Updated: 12:03 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Total Stock Market ETF

< Previous 1 2 3 4 5 6 7 8 9
...
96 97 Next >
KLAC Stock Is Falling Today Despite Q2 Beat And Slew Of Price Target Hikes – Wall Street Explains What’s Going On ↗
Via Stocktwits
Dan Ives Says AI Will Drive Apple’s 2026 Story As iPhone Price Hikes Linger: Report ↗
Via Stocktwits
Topics Artificial Intelligence
MSFT Stock Tumbled On Thursday – But Retail Sees The Decline As A Gift To Investors ↗
Via Stocktwits
SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time ↗
Via Stocktwits
News headline image
Why Is Barclays Still Underweight On Apple Despite Strong Q1 Earnings? ↗
Barclays flagged ongoing supply constraints that continue to limit the potential upside in iPhone shipments. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
SNDK Stock Soars Pre-Market Following Sandisk’s Blowout Q2 Report, Analyst Says Demand Is 'Exceptionally' Strong ↗
Raymond James analyst Melissa Fairbanks upgraded Sandisk to ‘Outperform’ from ‘Market Perform’ rating, with a price target of $725. 
Via Stocktwits
Topics Artificial Intelligence
What Triggered INUV Stock’s Sharp Sell-Off Today? ↗
Via Stocktwits
CVNA Stock Rebounds After Analysts Call Carvana Short Report 'Significant Misrepresentation Of Facts' ↗
Via Stocktwits
NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets? ↗
Via Stocktwits
News headline image
Why Did QNCX Stock Plummet Over 90% Today? ↗
The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 
Via Stocktwits
Topics Bankruptcy
News headline image
This ETF Has Underperformed the Stock Market For Years -- But I Think That's About to Change ↗
Due to certain macroeconomic conditions, it hasn't been a good stretch for this sector. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
Pullen Sells $3 Million of TETRA Technologies Stock ↗
This energy services firm provides specialized fluids and water management solutions to oil and gas operators worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Manager Gary Black Flags Doubts With Tesla Cybercab Design, Highlights Contrasting Consumer Preferences ↗
Black said in a post on X that the Cybercab is "wholly inconsistent” with the way consumers buy cars. 
Via Stocktwits
Tesla’s Robotaxi Rival Waymo Faces Fresh NHTSA Probe Following Pedestrian Incident Near School ↗
Via Stocktwits
A Tiny Float, Volatile Swings: Why Virtuix Is On Traders’ Radar ↗
Via Stocktwits
JOBY Stock Is Falling Pre-Market — What Is Dragging The Electric Air Taxi Developer's Shares Down? ↗
Via Stocktwits
News headline image
INOD Stock Is Rising Today — What Is Its New Partnership With Palantir About? ↗
Innodata announced that it has been chosen by Palantir to provide high-quality training data and data engineering services. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
LMT Stock Jumps 6% In Pre-Market – What’s Driving The Rally? ↗
Lockheed Martin delivered better-than-expected fourth-quarter topline and signed an agreement with the Department of War to expand missile production capacity. 
Via Stocktwits
News headline image
3 Wealth-Building Vanguard ETFs to Buy Hand Over Fist in 2026 ↗
Buying individual stocks isn't the only way to grow your nest egg. 
Via The Motley Fool
Topics ETFs
News headline image
Meta Q4 Earnings Beat Fuels New Price Target Hikes On AI, Ad Growth Optimism ↗
Barclays raised its price target to $800 from $770 and highlighted a sharp rebound in advertising momentum, noting that revenue growth above 30% has eased many lingering investor worries. 
Via Stocktwits
Topics Artificial Intelligence Earnings
CALC Stock Slumped 76% On Wednesday — Here’s Why ↗
Via Stocktwits
Tesla Q4 Earnings Beats Wall Street Expectations ↗
Via Stocktwits
Topics Earnings
BNAI Stock Again Soars More Than 40% — What’s The Latest Update Driving The Relentless Rally? ↗
Via Stocktwits
Why Is Richtech Robotics Stock Falling One Day After Announcing A Deal With Microsoft? ↗
Via Stocktwits
News headline image
Why Did SER Stock Surge Over 70% In Pre-Market Today? ↗
The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease. 
Via Stocktwits
News headline image
Tesla’s Car Lineup Will Soon Be Less S3XY As Musk Pitches $20B Pivot Into Autonomy, Robotics ↗
The company now eyes 2026 capital expenditure of about $20 billion, up from the $8.5 billion reported in 2025. 
Via Stocktwits
Topics Earnings Workforce
News headline image
Why Did Microsoft Shares Slump After-Hours Despite Q2 Earnings Beat? ↗
Microsoft reported a marginal decline in the growth of its cloud-computing unit while the company’s capital expenditure increased about 66% year-on-year. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Lantz Financial Buys $5 Million of Invesco BulletShares 2027 Corporate Bond ETF ↗
Invesco BulletShares 2027 Corporate Bond ETF tracks a portfolio of investment-grade corporate bonds maturing in 2027, targeting defined income and principal return at maturity. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases. 
Via Stocktwits
News headline image
Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss ↗
Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss. 
Via Stocktwits
Topics Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
96 97 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.